Peringatan Keamanan

Data regarding overdoses of nivolumab are not readily available.L12129 Common adverse effects include Rash, pruritus, cough, upper respiratory tract infection, and peripheral edema.L12129

Nivolumab

DB09035

biotech approved

Deskripsi

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).L12129 This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability.A35203 It was developed by Bristol Myers Squibb.L12129

Nivolumab was granted FDA approval on 22 December 2014.L12129 It is also available in combination with relatlimab under the brand name Opdualag.L41265,L49996,L50001

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The serum half life of nivolumab is approximately 20 days[A35187] with an elimination half life of 26.7 days.[A35290]
Volume Distribusi The volume of distribution at steady state when a dose of 10 mg/kg of nivolumab is administered is reported to be 91.1 mL/kg.[A35285] At doses ranging from 0.1 to 20 mg/kg the volume of distribution is reported to be 8L.[A35290]
Klirens (Clearance) The estimated clearance rate of nivolumab is 9.4 mL/h.[A35284] The clearance rate seems to be increased according to body weight.[A35290]

Absorpsi

Pharmacokinetic studies have suggested that nivolumab presents linear pharmacokinetics with a dose-proportional increase in peak concentration and AUC. The time to peak plasma concentration ranges between 1-4 hours.A35187 The absorption pharmacokinetic properties respective to the administration of a dose of 10 mg/kg are reported to be Cmax, Tmax and AUC of 242 µg/kg, 2.99 hours and 68100 µg\*h/mL respectively.A35285

Metabolisme

There have not been formal studies regarding the specific metabolism of nivolumab but as a human monoclonal antibody, it has been suggested to be degraded to small peptides and individual amino acids.L12618

Rute Eliminasi

There have not been studies regarding the specific route of elimination of nivolumab.L12618

Interaksi Obat

410 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Nivolumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Nivolumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Nivolumab.
Estrone Estrone may increase the thrombogenic activities of Nivolumab.
Estradiol Estradiol may increase the thrombogenic activities of Nivolumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Nivolumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Nivolumab.
Mestranol Mestranol may increase the thrombogenic activities of Nivolumab.
Estriol Estriol may increase the thrombogenic activities of Nivolumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Nivolumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Nivolumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Nivolumab.
Tibolone Tibolone may increase the thrombogenic activities of Nivolumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Nivolumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Nivolumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Nivolumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Nivolumab.
Zeranol Zeranol may increase the thrombogenic activities of Nivolumab.
Equol Equol may increase the thrombogenic activities of Nivolumab.
Promestriene Promestriene may increase the thrombogenic activities of Nivolumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Nivolumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Nivolumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Nivolumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Nivolumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Nivolumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Nivolumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Nivolumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Nivolumab.
Formononetin Formononetin may increase the thrombogenic activities of Nivolumab.
Estetrol Estetrol may increase the thrombogenic activities of Nivolumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Nivolumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nivolumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Nivolumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Nivolumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Nivolumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nivolumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Nivolumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nivolumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Nivolumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Nivolumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Nivolumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nivolumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Nivolumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nivolumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nivolumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Nivolumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nivolumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Nivolumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Nivolumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Nivolumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nivolumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nivolumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Nivolumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Nivolumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Nivolumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Nivolumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Nivolumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Nivolumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Nivolumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Nivolumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Nivolumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Nivolumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Nivolumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Nivolumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Nivolumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Nivolumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Nivolumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Nivolumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Nivolumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Nivolumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Nivolumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Nivolumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Nivolumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Nivolumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Nivolumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Nivolumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Nivolumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Nivolumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Nivolumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Nivolumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Nivolumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Nivolumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Nivolumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Nivolumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Nivolumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nivolumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Nivolumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Nivolumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Nivolumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Nivolumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Nivolumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Nivolumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Nivolumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Nivolumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Nivolumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Nivolumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Nivolumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Nivolumab.

Target Protein

Programmed cell death protein 1 PDCD1
Programmed cell death 1 ligand 1 CD274

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25798726
    Brahmer JR, Hammers H, Lipson EJ: Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11(9):1307-26. doi: 10.2217/fon.15.52. Epub 2015 Mar 23.
  • PMID: 28019091
    Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y: Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):58-66. doi: 10.1002/psp4.12143. Epub 2016 Dec 26.
  • PMID: 29158363
    Lee KW, Lee DH, Kang JH, Park JO, Kim SH, Hong YS, Kim ST, Oh DY, Bang YJ: Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. Oncologist. 2018 Feb;23(2):155-e17. doi: 10.1634/theoncologist.2017-0528. Epub 2017 Nov 20.
  • PMID: 26405320
    Solimando DA Jr, Waddell JA: Nivolumab and Olaparib. Hosp Pharm. 2015 May;50(5):356-66. doi: 10.1310/hpj5005-356.
  • PMID: 26273207
    Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, Omoto D, Ohmori S, Haruyama S, Sawada Y, Yoshioka M, Nishio D, Nakamura M: Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther. 2015 Aug 6;8:2045-51. doi: 10.2147/OTT.S62102. eCollection 2015.

Contoh Produk & Brand

Produk: 15 • International brands: 0
Produk
  • Nivolumab Bms
    Injection, solution, concentrate • 10 mg/ml • Intravenous • EU
  • Nivolumab Bms
    Injection, solution, concentrate • 10 mg/ml • Intravenous • EU
  • Opdivo
    Injection • 10 mg/1mL • Intravenous • US • Approved
  • Opdivo
    Injection • 10 mg/1mL • Intravenous • US • Approved
  • Opdivo
    Injection • 10 mg/1mL • Intravenous • US • Approved
  • Opdivo
    Injection • 10 mg/1mL • Intravenous • US • Approved
  • Opdivo
    Solution • 10 mg / mL • Intravenous • Canada • Approved
  • Opdivo
    Solution • 10 mg / mL • Intravenous • Canada • Approved
Menampilkan 8 dari 15 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul